PI-RADS 3级外周带病灶DCE-MRI药代动力学建模:初步诊断CS-PCa研究
本研究为双中心回顾性病例对照研究,纳入73例PI-RADS v2.1 3级外周带病灶且DCE-MRI主观阴性患者,评估DCE-MRI药代动力学参数诊断临床显著前列腺癌(CS-PCa)的价值。结果显示Ktrans和Ve在CS-PCa中显著高于ISUP 1级PCa及良性病变,AUC均为0.69,优于ADC。
要点
- PI-RADS 3级且DCE主观阴性时,Ktrans和Ve升高提示CS-PCa可能。
- ADC均值及10th百分位无法区分CS-PCa与ISUP 1级PCa或良性病变。
- Ktrans和Ve诊断CS-PCa的AUC均为0.69,需进一步研究验证。
局限性
- 回顾性病例对照设计,样本量较小(73例)。
- 仅纳入PI-RADS 3级外周带病灶,结论不能外推至其他PI-RADS类别或移行带。
- 需进一步研究确定哪些PI-RADS 3级患者应接受靶向活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine if pharmacokinetic modeling of DCE-MRI can diagnose CS-PCa in PI-RADS category 3 PZ lesions with subjective negative DCE-MRI.
MATERIALS AND METHODS: In the present IRB approved, bi-institutional, retrospective, case-control study, we identified 73 men with 73 PZ PI-RADS version 2.1 category 3 lesions with MRI-directed-TRUS-guided targeted biopsy yielding: 12 PZ CS-PCa (ISUP Grade Group 2; N = 9, ISUP 3; N = 3), 27 ISUP 1 PCa and 34 benign lesions. An expert blinded radiologist segmented lesions on ADC and DCE images; segmentations were overlayed onto pharmacokinetic DCE-MRI maps. Mean values were compared between groups using univariate analysis. Diagnostic accuracy was assessed by ROC.
RESULTS: There were no differences in age, PSA, PSAD or clinical stage between groups (p = 0.265-0.645). Mean and 10th percentile ADC did not differ comparing CS-PCa to ISUP 1 PCa and benign lesions (p = 0.376 and 0.598) but was lower comparing ISUP ≥ 1 PCa to benign lesions (p < 0.001). Mean Ktrans (p = 0.003), Ve (p = 0.003) but not Kep (p = 0.387) were higher in CS-PCa compared to ISUP 1 PCa and benign lesions. There were no differences in DCE-MRI metrics comparing ISUP ≥ 1 PCa and benign lesions (p > 0.05). AUC for diagnosis of CS-PCa using Ktrans and Ve were: 0.69 (95% CI 0.52-0.87) and 0.69 (0.49-0.88).
CONCLUSION: Pharmacokinetic modeling of DCE-MRI parameters in PI-RADS category 3 lesions with subjectively negative DCE-MRI show significant differences comparing CS-PCa to ISUP 1 PCa and benign lesions, in this study outperforming ADC. Studies are required to further evaluate these parameters to determine which patients should undergo targeted biopsy for PI-RADS 3 lesions.
引用
- Abreu-Gomez J, Lim C, Cron GO, et al. Pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI in PI-RADS category 3 peripheral zone lesions: preliminary study evaluating DCE-MRI as an imaging biomarker for detection of clinically significant prostate cancers. Abdom Radiol (NY). 2021. PMID: 33818626. doi:10.1007/s00261-021-03035-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。